Integration of genome-level data to allow identification of subtype-specific vulnerability genes as novel therapeutic

Edward C Schwalbe1,2, Lalchungnunga H1, Fadhel Lafta1,3

  • 1Biosciences Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle, UK.

Oncogene
|July 7, 2021
PubMed

Insights

Identifying cancer vulnerability genes offers new therapeutic targets. This study developed a bioinformatics method to find subtype-specific genes, proving effective in leukemia and medulloblastoma models for targeted cancer cell killing.

Area of Science:

  • Oncology
  • Genomics
  • Bioinformatics

Background:

  • Cancer treatments aim for efficacy and reduced toxicity.
  • Cancer genomes have numerous DNA methylation and gene expression changes.
  • Identifying cancer-specific vulnerability genes is a promising therapeutic strategy.

Purpose of the Study:

  • To develop a bioinformatics pipeline for integrating genome-wide DNA methylation and gene expression data.
  • To identify cancer subtype-specific vulnerability genes as novel therapeutic targets.
  • To validate the identified genes in distinct cancer models.

Main Methods:

  • Development of a bioinformatics pipeline integrating genome-wide DNA methylation and gene expression data.
  • Application of the pipeline to acute lymphoblastic leukemia and medulloblastoma datasets.
  • Functional validation using siRNA-mediated knockdown to assess proliferation and apoptosis.

Main Results:

  • Identification of 21 candidate subtype-specific vulnerability genes in acute lymphoblastic leukemia across five subtypes.
  • Identification of 15 candidate subtype-specific vulnerability genes in medulloblastoma across three subtypes.
  • Functional validation confirmed siRNA-mediated knockdown of candidate genes inhibited proliferation and induced apoptosis specifically in relevant cancer subtypes.

Conclusions:

  • A novel bioinformatics approach effectively integrates DNA methylation and gene expression data to identify cancer subtype-specific vulnerability genes.
  • The identified genes represent promising, novel therapeutic targets for precision cancer therapy.
  • The approach demonstrates broad applicability across different cancer types with high efficiency.